ArticleOncotarget2017

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.

Da Jung Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.